Centocor Inc. on Monday announced that it has closed thetransaction whereby it is entering a strategic alliance with EliLilly and Co. The terms, announced July 16, include acollaboration in the commercialization of HA-1A (Centoxin), fortreating infectious disease, Centocor said. Lilly paid Centocor$50 million for 2 million newly issued share of Centocor'scommon stock and an additional $50 million primarily forexpenses related to Centoxin.
Centocor stock closed Monday at $14.50 a share, down 25 cents.
(c) 1997 American Health Consultants. All rights reserved.